ArticleBiomolecules & biomedicine2026
Natural products modulate social behavior and gut microbiota in a valproic acid-induced zebrafish model of autism spectrum disorder.
Article in Biomolecules & biomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Natural products rich in honey- and plant-derived bioactive compounds are increasingly investigated as modulators of the gut-brain-microbiome axis, a pathway implicated in autism spectrum disorder (ASD)-related behavioral and gastrointestinal alterations. This study evaluated whether two novel formulations, a honey-based product (API) and a plant extract-based product (MOD), modulate exploratory, anxiety-like, and social behavior and intestinal microbiota composition in an adult valproic acid (VPA)-induced zebrafish model of ASD. Adult wild-type zebrafish were assigned to control, VPA (300 μM), API (500 mg/L), MOD (500 mg/L), VPA+API, and VPA+MOD groups. Behavioral outcomes were assessed using the novel tank test and a T-maze social behavior test, while intestinal microbiota was profiled by 16S rRNA gene sequencing using an Oxford Nanopore platform. VPA exposure induced mild locomotor and anxiety-like behavioral alterations, whereas API and MOD further modified exploratory and social behavioral readouts in both healthy and VPA-treated zebrafish. Both formulations increased the time spent near the social stimulus; however, this finding should be interpreted cautiously because treatment-associated hypolocomotion and altered exploratory activity may influence T-maze performance. Microbiota profiling revealed a Pseudomonadota-dominated community across all groups, with descriptive treatment-associated shifts in secondary phyla and diversity patterns, particularly in combined VPA+API and VPA+MOD groups. However, no significant differences in alpha diversity, beta diversity, or genus-level abundance remained after multiple-testing correction. These findings suggest that API and MOD may modulate behavioral outcomes in adult zebrafish exposed to VPA, while their effects on gut microbiota remain exploratory and require validation in larger, adequately powered studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.